AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Chardan Capital maintains 'Buy' rating on Rocket(RCKT).
The target price is $12, compare with $17 previously.
[Recent Rating]
| Date | Agency | Change | Rating | Rating (previously) | Target Price | Target Price(previously) |
|---|---|---|---|---|---|---|
| 2025-07-25 | B of A Securities | Downgrades | Neutral | Buy | $4 | $9 |
| 2025-07-24 | Needham | Maintains | Hold | Hold | $-- | $-- |
| 2025-07-24 | Chardan Capital | Maintains | Buy | Buy | $12 | $17 |
[Recent Earning Results] Rocket posted the Q1 of its 2025 financial results on 5/8/2025, reporting net income of USD -61.33 million in the first quarter, narrowing 1.16% from USD -62.05 million year over year.
[Company Profile] Rocket Pharmaceuticals, Inc. was incorporated under the laws of the State of Delaware on July 7, 1999. The company is a fully integrated, late-stage biotechnology company focused on the development of first, only and best in class gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet